← Leaderboards
Christian Michael Metallo
University Of California, San Diego
$6,622,491
Attributed
$8,034,278
Total exposure
6
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2014–25$2M$1.5M$1M$500K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,034,278 · 6
By mechanism
R01$6,185,127 · 3
S10$1,205,942 · 1
P30$449,459 · 1
R21$193,750 · 1
Top collaborators
- Maria Teresa Diaz Meco Conde6 shared
- Jong Min Rho1 shared
Most similar at University Of California, San Diego
Same institution · by research overlap
- Edward A Dennis$23,868,823
- Sameh S Ali$686,599
- Dmitri Simberg$8,108,683
- Longhou Fang$3,690,250
- Yun Sok Lee$2,488,189
Others in their field
Top investigators on “Pathway Interactions”
- David Heimbrook · Leidos Biomedical Research, Inc.$202,777,247
- Ralph Parchment · Leidos Biomedical Research, Inc.$146,974,543
- David R. Weir · University Of Michigan At Ann Arbor$129,316,139
- Daniel Ernest Ford · Johns Hopkins University$108,075,637
- David W Simpson · University Of Southern California$88,046,235
- Charles D. Blanke · Oregon Health And Science University$86,571,896
Research focus
Pathway InteractionsEnzymesIn VivoMetabolismMetabolicResponseCancer CellTumorigenesisTumorMitochondriaMetabolic PathwayProliferatingGrowthTumor MetabolismIn VitroGeneticBaseRegulationClinicAnabolismAmino AcidsCancer Cell GrowthMediatingGlycine
Grant awards (21)
A high-resolution tribrid mass spectrometer to amplify bioanalytical capacity at Salk Institute Mass Spectrometry core$1,205,942
S10 · FY2025 · OD · contact PI
Core 2: Heterogeneity of Aging$240,159
P30 · FY2024 · AG · contact PI
Non-essential amino acids and sphingolipid diversity in cancer progression$414,574
R01 · FY2023 · CA · contact PI
Core 2: Heterogeneity of Aging$209,300
P30 · FY2023 · AG · contact PI
Non-essential amino acids and sphingolipid diversity in cancer progression$414,574
R01 · FY2022 · CA · contact PI
Role of p62 in metabolic reprograming of the tumor stroma in prostate cancer$500,144
R01 · FY2021 · CA
Non-essential amino acids and sphingolipid diversity in cancer progression$235,100
R01 · FY2021 · CA · contact PI
Non-essential amino acids and sphingolipid diversity in cancer progression$156,242
R01 · FY2021 · CA · contact PI
Role of p62 in metabolic reprograming of the tumor stroma in prostate cancer$503,644
R01 · FY2020 · CA
Non-essential amino acids and sphingolipid diversity in cancer progression$364,668
R01 · FY2020 · CA · contact PI
Non-essential amino acids and sphingolipid diversity in cancer progression$362,020
R01 · FY2019 · CA · contact PI
Role of p62 in metabolic reprograming of the tumor stroma in prostate cancer$263,682
R01 · FY2019 · CA
Role of p62 in metabolic reprograming of the tumor stroma in prostate cancer$251,866
R01 · FY2019 · CA
Metabolic role of the neuronal Na+-dependent citrate transporter implicated in epilepsy$193,750
R21 · FY2019 · NS
Role of p62 in metabolic reprograming of the tumor stroma in prostate cancer$531,494
R01 · FY2018 · CA
Exploiting Metabloic Defects in Tumors with Mutant IDH1 and IDH2$321,625
R01 · FY2018 · CA · contact PI
Role of p62 in metabolic reprograming of the tumor stroma in prostate cancer$578,994
R01 · FY2017 · CA
Exploiting Metabloic Defects in Tumors with Mutant IDH1 and IDH2$321,625
R01 · FY2017 · CA · contact PI
Exploiting Metabloic Defects in Tumors with Mutant IDH1 and IDH2$321,625
R01 · FY2016 · CA · contact PI
Exploiting Metabloic Defects in Tumors with Mutant IDH1 and IDH2$321,625
R01 · FY2015 · CA · contact PI
Exploiting Metabloic Defects in Tumors with Mutant IDH1 and IDH2$321,625
R01 · FY2014 · CA · contact PI